Complete Compression Ultrasonography, Clinical Score, Underlying Risk Factors and D-Dimer Testing for Objective Evidence Based Diagnosis and Exclusion of Deep Vein Thrombosis and Alternative Diagnoses in the Primary Care and Hospital Setting

Jan Jacques Michiels1-3,4, Rob Strijkers1, Janneke M Michiels1, Wim Moossdorff2, Mildred La02 and Petr Dulicek6

1Goodheart Institute & Foundation, Bloodcoagulation & Vascular Medicine Science Center, Rotterdam, The Netherlands
2Department of Dermatology, Section Phlebology, Erasmus University Medical Center, Rotterdam, The Netherlands
3Star-Medical Diagnostic Center, Rijnmond Rotterdam, The Netherlands
4Department of Internal Medicine, HagaGlanden Hospital, The Hague, The Netherlands
5Department of Internal Medicine- Hematology, University Hospital and Faculty of Medicine in Hradec Kralove and Charles University, Prague, Czech Republic

Abstract
Superficial vein thrombosis is an integral part of venous thromboembolism (VTE) together with deep vein thrombosis (DVT) and pulmonary embolism (PE). The incidence of SVT is 1.6 per 1000 persons per year. The incidence of DVT is about 1.0 per 1000 persons per year in the general population, 1.8 per 1000 persons per year at age 65 to 69 years and 3.1 per 1000 persons per year at age 85 to 89 years. First episodes of DVT are in two-thirds of cases elicited by risk factors, including varicose veins, cancer, pregnancy/postpartum, oral contraceptives below the age of 50 years, immobility or surgery. Pain and tenderness in the calf and popliteal fossa may occur resulting from other conditions labeled as alternative diagnosis (AD) including Baker’s cyst, ruptured Baker’s cyst, torn plantaris tendon, hematoma, or muscle tears or pulls. The requirement for a safe diagnostic strategy of deep vein thrombosis (DVT) should be based on an objective post-test incidence of venous thromboembolism (VTE) of less than 0.1% with a negative predictive value for exclusion of DVT of 99.95% during 3 months follow-up. Modification of the Wells score by elimination of the “minus 2 points” for AD is mandatory and will improve clinical score assessment for DVT suspicion in the primary care and outpatient medical diagnostic setting. Compression ultrasonography (CUS) for proximal DVT overlooks distal DVT and is not cost-effective enough to rule in or out DVT. Complete CUS (CCUS) does pick up alternative diagnoses (AD) like Bakers cyst, muscle hematomas, old DVT, and superficial vein thrombosis (SVT). ADs with a negative CCUS include leg edema, varices, syringes, easily picked up by physical examination. The sequential use of CCUS followed by quantitative rapid ELISA-D-dimer testing and modified Wells’ clinical score assessment is cost-effective and objective diagnostic algorithm that can safely and effectively exclude and differentiate both DVT and AD in patients with suspected DVT. About 10 to 30% of patients with DVT develop overt PTS (CEAP, C4S) at one year post-DVT. DVT has a recurrence rate of about 20% to 30% after 5 years. A scoring system for lower extremity venous thrombosis (LET) extension on CCUS related to therapeutic implications is presented to prevent DVT recurrence and the post-thrombotic syndrome (PTS).

Keywords: Deep vein thrombosis; Complete compression ultrasonography; Alternative diagnosis; D-dimer; Clinical score; Primary care medicine

Primary Superficial Thrombophlebitis (SVT)
The incidence of superficial thrombophlebitis (SVT) is approximately 1.6 per 1000 persons per year. Several studies have confirmed the association of SVT and VTE. In a systematic review of patients with SVT, 6% to 44% of cases was associated with deep vein thrombosis (DVT), 20% to 33% with asymptomatic pulmonary embolism (PE) and 2% to 13% with symptomatic PE. Assessment of risk factor in the MEGA study a history of clinical SVT was associated with a 6.3-fold risk of DVT and a 3.9 risk of PE. In a study of 263 SVT patients, 30 (11.4%) developed DVT. Among 125 patients with SVT located in the great saphena vein, 16.8% developed DVT. Out of 138 patients with isolated SVT below the knee only 4.5% developed DVT. In a lower limb ultrasound study in 2646 patients 36 (9.3%) of the patients had combined DVT and PTS. These data indicate that primary SVT should be considered an integral part of DVT. The presence of inherited hypercoagulability or venous thrombosis in both SVT and DVT strongly supports a similar etiology and pathophysiology. In...
Deep-Vein Thrombosis (DVT)

Epidemiology

DVT has an annual incidence of 0.2% in the urban population [1]. The disease is rare in children under 15 year of age, but its frequency increases with age, with an incidence of about 1.0 per 1000 persons per year in the general population, 1.8 per 1000 persons per year at age 65 to 69 years and 3.1 per 1000 persons per year at age 85 to 89 years [2,3]. First-time episodes of DVT are in two-thirds of cases elicited by risk factors, including varicose veins, cancer, pregnancy/postpartum, oral contraceptives below the age of 50 years, immobility or surgery (Table 1) [2-8]. In the past the incidence of post-thrombotic syndrome (PTS) was found to be approximately 35 to 70% at 3 years in proximal DVT and rather uncommon in calf vein thrombosis (CVT) [4,5]. Randomized controlled studies with treatment of proximal DVT by adequate anticoagulation, early mobilization and long-term elastic compression for symptomatic PTS show that skin changes or ulceration (severe PTS) develop in 4-8% during long-term follow-up [5,8,9]. In a recent large management study of 1618 patients with a first DVT, the 1 year cumulative risk of PTS was 31% in women and 17% in men (overall 25% and severe 7%) [9]. The prevalence of DVT is equal in man and women, but seems to be slightly higher in young females below the age of 50 years [9]. The prevalence of DVT is comparable in black and white adults and is low in Asian populations. The risk of recurrence of venous thromboembolism is about 60% higher in men compared to women in one study [5], but equal in another large study [10].

Pathogenesis

In 1856, Virchow postulated that the main causes of thrombus formation consist of damage to the vessel wall, alterations in flow, and hypercoagulability. This conceptual model is called ‘Virchow’s triad’ and still valid today [11]. At time of thrombus formation in a leg vein which takes place under conditions as defined by Virchow, increased thrombin (IIa) generation converts fibrinogen into a fibrin clot (Figures 1 and 2). The maintenance of the fluidity and circulation of the blood and its ability of anticoagulant factors to prevent blood to clot (thrombosis) are essential for the maintenance of life. The extremely complex homeostatic mechanisms (Figure 1) of anticoagulant and procoagulant factors in concerted actions with the blood vessel endothelial cells on top of the fibrinolytic system (Figure 2) counteracts or stabilizes the fluidity of circulating blood to prevent thrombosis (fibrin formation). The anticoagulant, procoagulant and fibrinolytic systems depend upon consecutive enzyme activity with activators and inhibitors finely balanced at every stage (Figures 1 and 2). Alterations in blood coagulability, platelet reactivity and agglutinating power, with changes in blood flow and endothelial cell damage, are the precursors of intravenous thrombosis. Of these, the loss of normal function of the vascular endothelium may be of primary importance. A number of other hereditary thrombophilia factors and acquired thrombophilic conditions and elevated FVIII predispose to venous thrombosis (Figure 1 and Table 1) [12-15]. These include protein C and S (PC, PS) deficiency, antithrombin (AT) deficiency, activated protein C resistance (which is usually associated with Factor V Leiden genetic abnormality) factor II G20210A mutation and lupus anticoagulant [2,3,13-15]. Anticardiolipin antibody is also now recognized as an important cause of thrombosis [16-18]. Screening for these congenital thrombophilic factors as well as anticardiolipin antibody should be performed in patients having sporadic or recurrent thrombosis [19-21]. The use of oral contraceptive pill is a common risk factor for venous thromboembolism in women of reproductive age and surgical operations and pregnancy remain important triggers [22-40]. Prolonged immobility as in long-haul flights and hormonal influences, such as the contraceptive pill, are also well-documented risk factors [9,20,21].

Clinical features

The onset of a thrombosis is often ‘silent’ and may remain so. Symptomatic DVT or CVT may be the tip of a “clotted iceberg”. The cause of DVT may be idiopathic or provoked usually in the context of surgery, trauma, pregnancy and post-partum period. It commonly occurs at or about day 7 to 10 days after a surgical operation, parturition or the onset of an acute infection, concomitant with a rise in fibrinogen and platelet count. Between one-third and two-thirds of patients complain of some swelling and leg pain, usually in the calf [4]. An iliac vein thrombosis should be suspected if the whole leg is swollen and dusky in the absence of pain or cramps in the calf. Direct pressure on the calf muscles or over the course of the deep veins usually elicits direct tenderness in patients with suspected DVT or CVT. There may be a cyanotic hue to the leg and visuable superficial venous dilatation.

Table 1: Inherited and acquired risk factors for a first deep vein thrombosis: DVT.

<table>
<thead>
<tr>
<th>Inherited venous thrombophilia</th>
<th>Prevalence in general population</th>
<th>Prevalence in population with VTE</th>
<th>RR</th>
<th>Relative risk RR contribution OAC pill</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antithrombin AT</td>
<td>0.07-0.16</td>
<td>1-3 rare</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Protein C</td>
<td>0.2-0.4</td>
<td>3-5 less rare</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Protein S</td>
<td>0.03-0.13</td>
<td>1-5 rare</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>FV Leiden</td>
<td>3-15</td>
<td>20% frequent</td>
<td>5</td>
<td>20 fold-35 fold</td>
</tr>
<tr>
<td>Prothrombin</td>
<td>1-2</td>
<td>4-7</td>
<td>2-3</td>
<td></td>
</tr>
<tr>
<td>Total venous thrombophilia</td>
<td>5-6%</td>
<td>31% frequent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elevated F 8/10VF</td>
<td>11</td>
<td>25% frequent</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Epidemiology of DVT.
Once fibrin is formed, the fibrinolytic system is activated. Tissue plasminogen activator (t-PA) activates plasminogen bound to fibrin. Circulating urokinase plasminogen activator (u-PA) and the FXII-XI-kallikreine system activate circulating plasminogen into plasmin. Circulating Plasmin and plasminogen bound to fibrin degrade fibrin fragments e.g. D-dimer (clot lysis).

The temperature of the leg may be raised, and edema of one ankle is an important physical sign. However, chest pain or even cardiac arrest from pulmonary embolism may be the first presentation of a DVT. Pulmonary hypertension may follow repeated small emboli, and is associated with the development of progressive dyspnea.

**Differential diagnosis**

Estimates of clinical score as low, moderate, and high for the probability of proximal DVT, based on medical history and physical examination, have been advocated as the first step when DVT is suspected (Table 2). The diagnostic differentiation between DVT and alternative diagnosis (AD) by physical examination alone is problematic in routine daily practice indicating the need of objective testing by CUS to rule in and out DVT and AD. Pain and tenderness in the calf and popliteal fossa may occur resulting from other conditions labeled as alternative diagnosis (AD) including Baker’s cyst, ruptured Baker’s cyst, torn plantaritis tendon, hematoxia, or muscle tears or pulls. Cutaneous infection (e.g. erysipelas, cellulitis), lymphoedema, venous reflux, specially dermatitis, peripheral arterial disease, neurological and rheumatological causes should also be differentiated from DVT. Physicians in the primary care and hospital setting are faced with an extensive co-morbidity profile in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) due to a broad spectrum of disease related risk factors for DVT or venous thromboembolism (VTE) (Table 3) indicating the need to treat not only DVT but also the underlying disease to reduce the risk of DVT complications and recurrence as much as possible [2,3,9,14].

**Congenital Risk Factors for DVT (Thrombophilia)**

The risk of VTE in women with factor V Leiden is 5-6 fold higher in pregnancy [20]. The prevalence of different inherited thrombophilia in the general population and in patients with VTE and its calculated relative risk (RR) are summarized in Table 1. The frequency of hereditary thrombophilia in patients with confirmed idiopathic thrombosis occurring outside the clinical setting of surgery, trauma, or cancer is approximately 25%. The most common genetic predisposition in Caucasians is activated Protein C (APC) resistance, which is caused by the Factor V Leiden mutation in about 90%. Another cause is prothrombin G20210A gene mutation. Deficiency of physiological anticoagulant factors include deficiency of antithrombin (AT), Protein C (PC) or Protein S (PS), or heparin cofactor II. Combined deficiencies of Factor V Leiden, PC, PS, AT or the prothrombin mutation G20210A have been frequently described and they lead to a higher risk of thrombosis (20). There is an important interaction of Factor V and Factor II that leads to true synergistic potentiation with other transient risk factors for VTE such as pregnancy and oral contraceptives (12.20).

**Thrombophilia and Oral Contraceptives**

Oral contraceptives in heterozygotes for Factor V Leiden mutation increases the risk of VTE by =20-fold (95% CI: 4.29-43.6) (26) to =35-fold (95% CI: 7.8-154) [27]. This risk is further increased in users of third generation oral contraceptives to =50-fold compared with non-users without the mutation [27,28]. Heterozygotes for prothrombin (Factor II) variant (G20210A) on oral contraceptives have an =16-fold increased risk for VTE compared to an =6-fold increased risk of non-users (26). This variant may carry a higher =150-fold risk (95% CI:31-711) for the rare condition of cerebral vein thrombosis with the use of oral contraceptives [30-32]. For rare inherited thrombophilic conditions such as Protein C, Protein S or antithrombin deficiency from retrospective case review-type analyses [33-35]. Oral contraception is discouraged. Elevated Factor VIII coagulant levels (VIII:C) levels have
Phlebography is invasive, is inconclusive in 4 to 12% of cases, overrules alternative diagnoses like Bakers cyst and many others. A normal venogram of the leg veins in patients with suspected DVT excludes both proximal and distal DVT irrespective of clinical score with a negative predictive value (NPV) of 98.1 to 99% [47,48]. In a prospective study of 562 consecutive symptomatic patients with a first deep vein thrombosis in 35%, the distribution and extent of DVT was popliteal in 10%, popliteal-femoral in 42%, popliteal-femoral and common femoral vein in 5%, all proximal veins (popliteal femoral and common femoral) in 35% and proximal femoral or iliac vein in 8% (Figure 3) [49]. Phlebography is the gold standard to exclude and diagnose DVT in randomized clinical trials and do pick up asymptomatic and symptomatic early stage distal and proximal DVT (50). Due to its invasive nature phlebography has not become a routine test for DVT diagnosis and exclusion, and has been replaced by compression ultrasonography (CUS) [49,50].

As compared to phlebography as the reference gold standard to exclude and diagnose proximal DVT, the sensitivity of compression ultrasound (CUS) is 97% for proximal DVT [50]. CUS has many advantages over phlebography [49-51]. It is noninvasive, simple, easy to repeat, relatively inexpensive, and free of complications. It is safe to limit CUS estimation to the sub-popliteal, popliteal, and femoral veins for the diagnosis of symptomatic proximal DVT [49,50], but there are two main pitfalls (disadvantages) of proximal CUS [51]. First, calf vein thrombosis will be overlooked by CUS in the popliteal and femoral region. About one fourth to one third of calf vein thrombosis (CVT) may progress to proximal DVT within one week indicating the need to repeat CUS after one week. Second, isolated thrombi in the iliac and femoral veins within the adductor canal are relatively rare but difficult to detect and therefore overlooked by CUS in symptomatic patients with suspected DVT (Figure 3). In 1072 outpatients with a first suspicion of DVT in 5 management studies, the incidence of DVT on a venogram ranged from 26 to 46% for proximal DVT (popliteal and upper leg) and from 4 to 10% for CVT [48,51]. About a fourth of CVT extends into the proximal veins within a few days to 1 week. In 1998, Cogo et al and others extended CUS to all segments of the common femoral, femoral poplitea and subpopliteal region (E-CUS, Figure 4) [51,52]. After a first negative CUS overlapping CVT in routine daily practice, a repeated CUS in prospective management studies will become positive in 2 to 3% within 1 week [53]. Five management studies indeed showed that the postest incidence of VTE after a first negative CUS ranged from 1.7 to 3.0% indicating a NPV 98.3 to 97% [48,50].

### Strategies for Safe and Effective Exclusion and Diagnosis of DVT

#### Clinical score

The distribution of the Wells clinical score estimates of DVT in the different clinical score groups from 10 studies of outpatients with suspected DVT revealed that the proportion of patients belonging to the low clinical score group was the highest when the overall prevalence of DVT was the lowest (<20%) and vice versa [47,48]. The overall prevalence of DVT ranged from 18 to 14%. The relative frequency of documented DVT by CUS in the low, moderate and high Wells score ranged from 2.6-14%, from 17-56%, and from 32-76% respectively [47,48,51]. Accurate differentiation between alternative diagnosis (AD) and DVT or the absence of both in outpatients with suspected DVT by clinical assessment according to Wells scores is subjective, depends on experienced supervision by highly specialized clinicians in carefully controlled clinical settings, and appears absolutely not to be reproducible in multidisciplinary settings in hospitals or in multicenter
clinical trials. Consequently we decided in 1998 the elimination of the “score of minus 2 for AD (Table 2) in our prospective DVT management study of more than 2000 outpatients with suspected DVT referred to our medical diagnostic center in Rotterdam between 2005 and 2012 to exclude or diagnose DVT and AD (Figures 5-7, manuscripts in preparation). In these prospective DVT studies we used the Rotterdam clinical score assessment as a fill-in form (Table 2) at time of DVT and AD exclusion and diagnosis in the primary care setting of a medical diagnostic laboratory (equivalent to outpatient hospital setting). ADs) like Baker’s cyst etc. has been scored in 1997 by Wells et al as minus 2 points (AD-2). This AD-minus 2 scoring procedure is not reproducible in daily clinical hospital and outpatient practice and unreliable as compared to complete CUS (CCUS) evaluation [47,48,51-56]. According to the Rotterdam modification a score of 0 (asymptomatic) means a low probability, a score of 1 or 2 a moderate probability, and a score of 3 or more a high probability for DVT (Table 2).

**Qualitative and Quantitative D-dimer Testing for DVT Exclusion**

During thrombus formation in a leg vein, thrombin (IIa) activates FXIII (XIIIa) and degrades fibrinogen into fibrin peptides (A and B) and fibrin monomers, which spontaneously form polymers, from which FIIIIa mediated firm fibrin clots are formed (Figure 2, [57]). Once fibrin (venous thrombosis) is formed the fibrinolytic process is initiated by endogenous tissue plasminogen (t-PA, urokinase plasminogen activator (u-PA) and the FXII-XI-kallikreine system. T-PA activates plasminogen bound to fibrin (thrombus) (Figure 2), Whereas u-PA and the FXII-XI-kallikreine system activates circulating plasminogen. Plasmin degradation of cross-linked fibrin results in fibrin fragment E and D-dimer, which consist of two covalently bound D-domains. D-dimer is a final and stable degradation product of a cross-linked fibrin clot (Figure 2) [57].

Determination of the D-dimer level is a must in the diagnosis and treatment of patients with venous thrombotic disease (Figure 5). D-dimer measurement has gained a prominent role for ruling out DVT because of its high sensitivity [47,48,58,59]. The specificity of D-dimer is low because its concentrations can be raised in various other conditions, such as inflammation, pregnancy, or cancer [60-72]. The qualitative D-Dimer test SimpliRed has a sensitivity of 89%, a specificity of 77% and a NPV of 96% for the exclusion of DVT [67]. In three large prospective studies of 2239 outpatients with suspected DVT, the sensitivity of a normal quantitative ELISA VIDAS D-dimer test (cut-off level <500 ug/L) varied between 98% and 99.9% irrespective of clinical score [63-65] (Figure 6). The quantitative ELISA VIDAS test at a cut of level of 1000 ug/ml has a sensitivity of 89% to 89%, a specificity of 56% to 68% and a NPV of 96% in two large studies [47,48,68]. In large outcome studies, the sensitivity of a normal turbidimetric assay (Tinaquant, cut-off <500 ug/L for the exclusion of DVT) is between 98% and 99.9%.
have been extensively studied and recommended to be a safe and the most cost-effective diagnostic work-up of DVT (Figures 7 and Table 2) [47,48,51,60,65,68].

Oudega and his team of primary care investigators assessed in 2008 the diagnostic accuracy of five point of care D-dimer assays for the exclusion of DVT (N=200, Table 4). In 200 primary care patients with suspected DVT of whom 24 (12%) had DVT on CUS both CUS results and the results of all D-dimer assays were available. At the manufacturer provided threshold, the sensitivity and negative predictive value of the rapid ELISA D-dimer test were 100% at a specificity of 40.3% whereas all other D-dimer assays showed sensitivities of 95.8% or lower at negative predictive values somewhat higher than 98% simple because of the low prevalence of DVT (12%) (Table 4)

**Complete Compression Ultrasonography (CCUS)**

The advantage of (CCUS) is that it does pick up alternative diagnoses (AD) like Bakers cyste, muscle hematomas, old DVT, and superficial vein thrombosis (SVT). Other alternative diagnosis with a negative CUS include leg edema, varices, erysipelas etc (Figures 6 and 7). The NPV of CCUS by experienced specialists in the medical diagnostic laboratory setting or outpatient ward in 3 large management studies with a prevalence of DVT from 14 to 33% is high, 99.5% [54-56]. As compared to CUS and CUS-D-dimer strategy, CCUS reduces the number of CUS significantly 170 and 130 to 100 per 100 cases with a suspicion on CVT, DVT AD (Table 5). CCUS in a prospective clinical study of 623 patients with suspected DVT detected a total of alternative diagnoses in 248 cases (60.5%) [54]. An underlying disease and abnormal CCUS was found in 172 (42%), with venous reflux in 93, muscular lesion in 20, hemotoma in 24, and Baker’s cyst in 35 (8 ruptured) [54]. In addition an underlying disease and normal CCUS was found in 77 (18.5%) including peripheral artery disease, cutaneous infection, neurologic/rheumatologic disease and lymphedema [54]. These clinical observations [54-56] indicate that CCUS is far superior to CUS and E-CUS (Figure 5) and should become the first objective step for the diagnosis and exclusion of CVT, DVT and AD (Figure 7).

**CCUS, D-dimer and Clinical Score Strategy to Rule in and out DVT**

Based on personal experiences and evidence-based objective diagnostic tools we developed the Rotterdam concept (Figures 6 and 7) to safely exclude and diagnose deep vein thrombosis [47,48,51] because of the following reasoning. First, a negative CCUS and a negative VIDAS test (<500 ng/ml) exclude DVT with a sensitivity and specificity of 99.99% irrespective of clinical score assessment. After a first negative CCUS the prevalence of DVT in routine daily practice is uniformly low, 2% to 3% [47,48,69-72]. The general application of two non-specific and rather insensitive methods for DVT and AD exclusion by the combination of a negative SimpliRed (Simplify) and low clinical score should be estimated as not safe enough mainly because the prevalence of DVT in the low clinical score group may vary widely (3% to 12%) [47,48,69]. According to our experiences and analysis of literature findings [48,73] the safest and most effective and sensitive approach for DVT and AD exclusion is to start with objective testing with CCUS, followed by a qualitative or less sensitive D-dimer test without the use or need of clinical score assessment (Figures 4 and 7). A first negative CCUS and a negative ELISA VIDAS test (<500 ug/mL) excludes DVT irrespective of clinical score assessment (left arm, Figure 7). The combination of a negative CCUS, a low clinical score and a D-dimer level of ELISA VIDAS <1000 ug/ml, Tinaquant <800 ug/ml or negative SimpliRed (Simplify) will safely exclude deep vein thrombosis
Management of DVT in the Primary Care and Hospital Setting

Below-knee stockings appear to be as effective as thigh-length stockings for relief of swollen acute DVT legs and for symptomatic relief of the post-thrombotic syndrome (PTS). In acute DVT patients (21,41,73,74 MECS may also be used for symptomatic relief of swollen acute DVT legs combined with low-molecular weight heparins (LMWH) followed by vitamin K antagonists (VKA) or novel oral anticoagulants (NOACs)). Pneumatic compression therapy has been proved to be effective, but is probably only realistic in post-operative circumstances, and it has shown to be effective in for example elective knee or hip replacement [21,41,74].

Clinicians should be aware of co-morbidity as risk factors for DVT, particularly in elderly bedridden patients with widespread skin disease, infection, or other co-morbidities (Table 3). The incidence of DVT among general medical patients with reduced mobility ranges from 10 to 26% [74]. Prolonged sitting is as harmful as lying. Active exercise and early mobilization is desirable when possible. All hospitalized general medical patients should be assessed for venous thromboembolism risk factors [21]. Those patients classified to be at moderate at high risk should be given thrombosis prophylaxis with LMWH (4000 U or more once daily).

Surgical patients may be classified as having a low, moderate, or high thrombosis embolic risk. Low risk patients are patients under 60 years of age without any other risk factors for venous thromboembolism undergoing minor surgery (e.g. laparoscopic surgery, transurethral surgery, or out-patient surgery). These patients should be mobilized early and no additional thrombosis prophylactic regimen is required. The group of moderate risk patients consist of patients older than 60 years undergoing minor surgery, and patients younger than 60 years who undergo major surgery, but have no additional risks. These patients should be treated with LMWH (≤ 3400 U daily) or NOACs. Patients with high bleeding risk may be treated by MECS or intermittent pneumatic compression alone. High risk patients for venous thromboembolism are patients undergoing major surgery and being over 60 years of age, or having additional risk factors. These patients should be treated with LMWH (>3400 U daily). MECS may be used as additional treatment for symptomatic efﬁcacy of swollen legs [21,74].

Patients undergoing major orthopedic surgery face an overall DVT rate ranging from 40 to 60% and a proximal DVT rate between 10 to 30% without thrombosis prophylaxis. The general consensus is that these patients should receive adequate thrombosis prophylaxis with LMWH, or one of the novel oral anticoagulants (NOACs). Patients receiving prolonged treatment duration (4 to 5 weeks) in hip surgery showed a significant reduction of DVT rate [21,74]. The introduction and use of the novel oral anticoagulant (NOAC) Xa or IIa inhibitors are out of scope in this review.

Standard Anticoagulant Treatment of DVT

The diagnosis DVT should be confirmed as soon as possible by compression ultrasound if a DVT is suspected. Initial treatment with a LMWH is given subcutaneously once a day (150 to 200 IU/kg). LMWH is effective in an outpatient setting [3,21]. As soon as the diagnosis of DVT is conﬁrmed, vitamin K antagonists (VKA e.g. warfarin) should be added to the heparin. VKA decrease the functional vitamine-K dependent procoagulant factors II, VII, IX en X to a therapeutic level ranging from 40 to 60% and a proximal DVT rate between 10 to 30% without thrombosis prophylaxis. The general consensus is that these patients should receive adequate thrombosis prophylaxis with LMWH, or one of the novel oral anticoagulants (NOACs). Patients receiving prolonged treatment duration (4 to 5 weeks) in hip surgery showed a significant reduction of DVT rate [21,74]. The introduction and use of the novel oral anticoagulant (NOAC) Xa or IIa inhibitors are out of scope in this review.

Standard Anticoagulant Treatment of DVT

The diagnosis DVT should be confirmed as soon as possible by compression ultrasound if a DVT is suspected. Initial treatment with a LMWH is given subcutaneously once a day (150 to 200 IU/kg). LMWH is effective in an outpatient setting [3,21]. As soon as the diagnosis of DVT is confirmed, vitamin K antagonists (VKA e.g. warfarin) should be added to the heparin. VKA decrease the functional vitamine-K dependent procoagulant factors II, VII, IX en X to a therapeutic level of about 1/3 of normal (anticoagulation degree of INR 2.5-3) (Figure 1). LMWH inhibits via binding to AT the activated factors Xa en IIa (Figure 1). The new oral Xa-inhibitors selectively inhibit
bloodcoagulation at the critical location (Xa) of the common place where the intrinsic and extrinsic coagulation pathways (Figure 1) with the ultimate consequence of decreased prothrombinase activity and decreased thrombin (IIA) generation (adequate anticoagulation without the need of laboratory monitoring).

Monitoring of anticoagulation is done by the prothrombin time, expressed in terms of the international normalized ratio (INR). A ratio between 2.0. and 3.0 should be achieved for the most adequate anticoagulation, and the lowest risk of bleeding. Heparin can be discontinued after 5 to 7 days, as long as the INR is stable and 2.0 or greater [3,41]. Idiopathic venous thromboembolism is generally treated for 6 months, but anticoagulation may be for life for those with continuing risk [75]. LMWH and oral anticoagulants should be combined with ambulatory compression therapy or medical elastic stockings (MECS). Once edema has been reduced completely, class II MECS (23 to 32 mm Hg at B measurement) are prescribed to be worn for a period of 2 years. If, during the use of MECS, edema is still present, class III MECS (34 to 46 mm Hg at B measurement) are prescribed [76]. In about half of the acute DVT patients leg swelling disappears with no signs PTS at 3 to 6 months post-DVT obviating the need to wear MECS. Vena cava filters are effective in preventing the short-term incidence of pulmonary embolism in patients with proximal DVT, but they do not affect mortality. Vena cava filters are thrombogenic and double the recurrence risk of DVT, or after recurrent DVT [3].

Risk of PE, DVT Recurrence and the Post-thrombotic Syndrome

Pulmonary embolism, post-thrombotic syndrome (PTS) and recurrent thrombosis are the main complications of DVT. If proximal DVT is left untreated, clinical pulmonary embolism will occur in 26 to 67% of the cases, and is associated with a mortality rate of 11 to 23% [77,78]. The incidence of pulmonary embolism decreases to 5% and the mortality to less than 1% under treatment [77]. About 10 to 30% of patients with DVT develop overt PTS (C4,5) at one year post-DVT. DVT has a recurrence rate of about 20% to 30% after 5 years, but the rate varies depending on the presence of risk factors and prolonged anticoagulation if indicated [78-82]. PTS is a chronic condition that affects the deep venous system, may extend to the superficial venous system of the legs in patients with a documented history of deep vein thrombosis and has been discussed in our review on DVT, DVT and PTS: bridging the gap [83,84]. In 2012 Arnoldussen and and Wittens proposed a simple scoring system for lower extremity venous thrombosis (LET) extension on CCUS [85]. The LET score can be used to expand and standardize the documentation of DVT localization and extension at time of DVT diagnosis to predict DVT recurrence rate and the risk on PTS. The LET score is helpful to identify optimal treatment options in patients with acute DVT in the primary care and hospital setting (Figure 8) [85-87]. In 2013/2014, Strijkers, Moossdorff and Michiels designed and performed the DVT-PTS Bridging the Gap pilot study and could prove the feasibility to study the LET concept (Figure 8) in a large prospective evaluation on DVT and DVT recurrence in rate to reduce PTS in the primary care and hospital setting. The preliminary results in 30 newly diagnosed DVT patients produced good evidence that complete recanalization of DVT in the calf (LET Class I) and in the popliteal/femoral region (LET Class II) is predicted to occur in about one third of DVT at 3 months post-DVT with no RVT on CUS [88-90]. This will be associated with no or low risk on DVT recurrence, no reflux on DUS and low risk on PTS obviating the need of wearing stockings and no need for extended anticoagulation (Figure 8). When the recanalisation of the popliteal-femoral region is delayed and incomplete at 3 months post-DVT with RVT and/or reflux on CUS due to valve destruction in the popliteal/femoral region at time points 3 months post-DVT will be associated with a high risk of DVT recurrence as the cause of PTS [88-90] indicating the need to extend anticoagulation preferentially with NOAC (Figure 8) [53-55]. Extension of proximal popliteal/femoral DVT into the illeofemoral region or isolated acute illeofemoral DVT with a swollen lower and upper DVT leg are candidate for Catheter Accelerated thrombolysis Versus Anticoagulation (CAVA) as the risk of severe PTS by anticoagulation alone in LET Class III/IV DVT patients alone is irreversible and high (Figure 8) [85-87].

A possible prospective study design on DVT and PTS bridging the gap in shown in Table 6. A clinical examination of the assessment of the risk on PTS by DUS should be performed in routine clinical practice at 1 month, 3 and 6 months, 1 year, and 2 years post-DVT to determine whether there is still a need for wearing MECS in symptomatic PTS, and to see whether additional treatment is necessary (Table 6 and Figure 8). About one third of DVT patients have normal DUS 3 months post-DVT and do not develop PTS after 3–9 months post-DVT obviating the need to wear MECS and anticoagulation (study arm 1, Table 6). In the event that RVT at 3 months post-DVT and reflux of the deep venous system is found at and after 3 months post-DVT, wearing MECS and anticoagulation with vitamin K antagonist (VKA) or novel oral anticoagulants (NOAC) should be continued (study arm 2, Table 6). Three months post-DVT appears to be the appropriate time points to determine the group of patients who do not have RVT and the group who do have RVT and are at high risk for DVT

<table>
<thead>
<tr>
<th>Co-morbidity profile in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and disease related risk factors for DVT or venous thromboembolism (VTE)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risk Factors</strong></td>
</tr>
<tr>
<td><strong>Co-morbidity</strong></td>
</tr>
<tr>
<td>Acute medical illnesses, e.g. acute myocardial infarction, heart failure, respiratory failure, infection</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
</tr>
<tr>
<td>Antiphospholipid syndrome</td>
</tr>
<tr>
<td>Dyslipoproteinaemia</td>
</tr>
<tr>
<td>Nephrotic syndrome</td>
</tr>
<tr>
<td>Paroxysmal nocturnal haemoglobinuria</td>
</tr>
<tr>
<td>Myeloproliferative diseases</td>
</tr>
<tr>
<td>Behcet’s syndrome</td>
</tr>
<tr>
<td>Venous steal</td>
</tr>
<tr>
<td>Prolonged bed rest</td>
</tr>
<tr>
<td>Prolonged immobilisation</td>
</tr>
<tr>
<td>Inherited thrombophilia</td>
</tr>
<tr>
<td>Essential thrombocytosis</td>
</tr>
<tr>
<td>Central venous catheter</td>
</tr>
<tr>
<td>Vena cava filter</td>
</tr>
<tr>
<td>Intra venous drug use</td>
</tr>
</tbody>
</table>

Table 3: Co-morbidity profile in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and disease related risk factors for DVT or venous thromboembolism (VTE) (2,3,9,14).
recurrence and develop PTS. Patients with PTS CEAP 2, 3 and 4 at 3 to 6 months post-DVT seems to us candidates for long-term extended anticoagulation preferentially with low dose Direct Oral Anticoagulant (NOAC) inhibitors such as used in the post-operative orthopedic surgery setting (Study arms 3 and 4, Table 6). There is a need for short-term anticoagulant treatment of symptomatic calf vein thrombosis (CVT) to prevent DVT extension because CVT potentially extends into the proximal popliteal and femoral veins, which can obstruct the deep venous system and place the patient at higher risk of pulmonary embolism and more severe post-thrombotic morbidity (Figure 8). About one fourth of distal vein or CVT will extend into the popliteal and femoral region within 1 or 2 weeks, which is associated with increased risk of DVT recurrence and PTS. Extended anticoagulation is mandatory in the event of reflux with or without PTS at 6 months, 12

<table>
<thead>
<tr>
<th>D-Dimer assay</th>
<th>Cut-off value</th>
<th>Sensitivity% (CL)</th>
<th>Specificity% (CL)</th>
<th>NPV% (CL)</th>
<th>ROC area% (CL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vidas</td>
<td>500 ng/ml FEU</td>
<td>100(93-100)</td>
<td>40.3(33-48)</td>
<td>100(97-100)</td>
<td>0.89(0.83-0.95)</td>
</tr>
<tr>
<td>Pathfast</td>
<td>0.57 µg/ml FEU</td>
<td>95.8(88-100)</td>
<td>34.7(28-42)</td>
<td>98.4(95-100)</td>
<td>0.89(0.83-0.96)</td>
</tr>
<tr>
<td>Cardiac</td>
<td>0.5 µg/ml FEU</td>
<td>95.8(88-100)</td>
<td>56.8(50-64)</td>
<td>99.0(97-100)</td>
<td>0.87(0.80-0.94)</td>
</tr>
<tr>
<td>Triage</td>
<td>0.35 µg/ml D-DU</td>
<td>95.8(88-100)</td>
<td>47.7(40-55)</td>
<td>98.8(97-100)</td>
<td>0.87(0.79-0.95)</td>
</tr>
<tr>
<td>Simplify</td>
<td>N.A</td>
<td>91.7(81-100)</td>
<td>63.1(56-70)</td>
<td>98.2(96-100)</td>
<td>N.A</td>
</tr>
</tbody>
</table>

Table 4: Diagnostic accuracy of five point of care D-dimer assays for the exclusion of deep vein thrombosis (DVT) in the primary care setting in a cohort of 200 patients with suspected DVT and a prevalence of DVT of 12% on a first compression ultrasonography (CUS) and repeated CUS within one week. V28-42. FEU: Fibrin Equivalent unit; N.A: Not applicable; D-DU: D-Dimer Unit; CI: 99% Confidence. Interval; NPV: Negative Predictive Value; n: Number of Patients.
months, and 24 months post-DVT to prevent DVT recurrence as the cause of PTS or increase of PTS severity. This has to be demonstrated in a large prospective cost-effective, safety outcome study (Table 6 and Figure 8).

Acknowledgement

The present report was initiated and written by Dr. Michiels in his position of Senior Investigator, Phlebology and Thrombosis, at the Department of Dermatology, Erasmus University Medical Center Rotterdam, The Netherlands, in the period between January 1, 2007 and January 1, 2014 in a joint venture with Dr. HA Martino Neumann, Rotterdam, The Netherlands and Dr Strijkers in his position of Clinical Investigator on DVT and PTS 2011-2014, Department of Vascular Surgery University Medical Center, Maastricht

References

1. Nordström M Lindblad B, Bergqvist D, Kjellström T (1992) A prospective study in a large prospective cost-effective, safety outcome study (Table 6 and Figure 8).

Acknowledgement

The present report was initiated and written by Dr. Michiels in his position of Senior Investigator, Phlebology and Thrombosis, at the Department of Dermatology, Erasmus University Medical Center Rotterdam, The Netherlands, in the period between January 1, 2007 and January 1, 2014 in a joint venture with Dr. HA Martino Neumann, Rotterdam, The Netherlands and Dr Strijkers in his position of Clinical Investigator on DVT and PTS 2011-2014, Department of Vascular Surgery University Medical Center, Maastricht

References


